Other substances

Bedaquiline

A diarylquinoline antimycobacterial agent. 

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
4
 AI-suggested references
0
 Clinical trials

General information

Bedaquiline is a mycobacterial ATP synthase inhibitor used for the treatment of tuberculosis (ChEBI). 

Bedaquiline on DrugBank
Bedaquiline on PubChem
Bedaquiline on Wikipedia


Marketed as

SIRTURO

 

Structure image - Bedaquiline

CN(C)CC[C@@](C1=CC=CC2=CC=CC=C21)([C@H](C3=CC=CC=C3)C4=C(N=C5C=CC(=CC5=C4)Br)OC)O

Supporting references

Link Tested on Impact factor Notes Publication date
Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2
3CLpro Small molecule Enzyme assay In vitro 		in vitro enzyme assay 3.75

Inhibited the SARS-CoV-2 3C-like protease in vitro with IC50 of 18.7 μM.

 Oct/25/2020

AI-suggested references

Link Publication date
Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic.
Feb/06/2022
Artificial intelligence approach fighting COVID-19 with repurposing drugs
May/15/2020
Discovery of re-purposed drugs that slow SARS-CoV-2 replication in human cells
Oct/15/2021
Repurposing Based Identification of Novel Inhibitors against MmpS5-MmpL5 Efflux Pump of Mycobacterium smegmatis: A Combined In Silico and In Vitro Study
Sep/20/2021
Export (.csv)